A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 21 Sep 2017 Planned End Date changed from 1 Jul 2020 to 15 Jun 2021.
- 21 Sep 2017 Planned primary completion date changed from 1 Jul 2020 to 15 Jan 2021.
- 21 Sep 2017 Status changed from not yet recruiting to recruiting.